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Mesenchymal stem cellsIn recent years, there has been a shift toward tissue-engineering strategies using stem cells for plastic and
reconstructive surgical procedures. Therefore, it is important to develop safe and reproducible protocols
for the extraction of adipose-derived stromal cells (ASCs) to allow cells to be stored in liquid nitrogen for
future needs.
The aspirated liposuction obtained from healthy donors were immediately processed after the suction
using a protocol developed in our laboratory. The resulting stromal vascular fraction (SVF) was then
characterized by the presence of adipose-derived stromal cells, at later stage frozen in liquid nitrogen.
After that, cells were thawed and again characterized by adipose-derived stromal cells, cellular survival,
differentiation ability and Colony Forming Unit-Fibroblast like colonies (CFU-F).
Extraction and freezing of cells contained in the stromal vascular fraction demonstrate that thawed
cells maintain the full capability to grow and differentiate in culture.
The advent of adipose-derived stromal cells use in tissue engineering will assume a wide role in
esthetic restoration in plastic surgery. It is thus important to develop clinically translatable protocols
for the preparation and storage of adipose-derived stromal cells. Our results show that adipose-derived
stromal cells in serum free can easily be frozen and stored in liquid nitrogen with retention of 85% of cell
viability and 180,890 cell/g yield plus normal proliferative capacity and differentiation potential com-
pared with fresh controls. These observations set the basis for adipose-derived stromal cells banking.
 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).Introduction
The importance and the role of adipose tissue has been lately
greatly re-evaluated after the discovery that adipose tissue is the
largest endocrine organ, which is able to interact with all major
organs via production of a wide range of hormones and cytokines
[25]. Furthermore, many groups working independently have
shown that adult stem cells derived from white adipose tissue
can differentiate along multiple pathways raising great hope in
regenerative medicine, considering that adipose tissue can be an
abundant source of therapeutic cells [17].Mesenchymal stem cells (MSCs) were ﬁrst isolated from bone
marrow and then turned out to be able to regenerate rudiments
of bone and support hematopoiesis in vivo [8]. They also provided
an hemopoietic microenvironment in vitro [3,16] and circulated in
the blood between tissues [15,14,7]. Plastic adherent populations
isolated from bone marrow were proved to be functionally hetero-
geneous and ﬁbroblast colony-forming unit-derived colonies were
made up of undifferentiated stem cells and progenitor cells. These
cells were multipotent and they were able to differentiate into
mesenchymal cells types, including osteoblasts, chondrocytes,
and adipocytes. Because of the fact that MSCs are generated from
the stromal component of bone marrow, they were later renamed
as multipotent mesenchymal stromal cells (with the same
acronym) to reﬂect their origin and biological properties [6]. MSCs
are found in many tissues, including bone marrow, umbilical
cord, placental tissue and adipose tissue. However, adipose
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cells, ASCs) for autologous therapies are easier to obtain than MSCs
from other tissue sources, such as bone marrow, opening the door
for potential Advanced Therapy Products [17].
Recently, human ASCs were successfully reprogrammed into
embryonic stem cell-like colonies (induced pluripotent stem cell,
iPS) faster and more efﬁciently than adult human ﬁbroblasts
[20,1], using the strategy developed by Yamanaka and co-workers.
ASCs cells are also increasingly appreciated in the plastic and
reconstructive surgical procedures, where the shift toward
tissue-engineering strategies using stem cells is now apparent
[22]. Currently available reconstructive surgery using synthetic
materials or autologous fat transplants are often unsatisfactory,
which is also due to the long-problems of volume maintenance.
Transplanted ASCs may overcome these problems via real stem
cell-based regeneration of the tissues and thus introducing the
development of clinically translatable protocols for the preparation
and storage of ASCs for tissue engineering.
In this report we validate a safe and reproducible protocol to
extract and freeze ASCs from lipo-aspirated and we demonstrate
that ASCs can be frozen and thawed without damaging or compro-
mising their stem cell properties.Materials and methods
Surgical techniques and adipose tissue sampling
Liposuction was performed during surgical esthetic procedures.
Women older than 18 years (range 18–53 years) in good health
and HIV (Human Immunodeﬁciency Virus), HCV (Hepatitis C Virus)
and HBV (Hepatitis B Virus) negative were included in this study
after obtaining their written informed consent.
Liposuction procedure started with a preemptive analgesia:
Calecoxib 200 mg per os (400 mg for patients whose weight is over
50 kg) about 1 h before surgery. Before going to the operating
room, we administered an intravenous infusion with 100 ml of
NaCl 0.9%, Ranitidine 50 mg, Ondansetron 4 mg, Desametason
8 mg, Cefazolin 2 g and a sedation with Midazolam 1 mg bolus
I.V. Sedoanalgesia was performed with Sufentanil bolus I.V.
(0.05 lg/kg) and Propofol continuous infusion.
The access points of the cannula were inﬁltrated with a physio-
logic solution containing 0.1% lidocaine and 1:100,000 adrenalin.
The composition and the quantity of the inﬁltrated solution
depended on the volume of the adipose tissue to be removed and
it corresponded to a 1:1 proportion with the aspirated amount. A
negative pressure of 400 mm Hg was applied to the cannula
connected to a 60 ml syringe for aspiration.Isolation of stromal vascular fraction (SVF)
The isolation of the SVF was performed by means of a protocol
we developed in our laboratories [2]. This isolation protocol is
based on the use of a 100 ml syringe (Omniﬁx 100 ml with Luer
Adaptor, B. Braun AG, Melsungen, Germany) as a separation funnel
(Patent pending). The protocol is based on the fact that adipose
tissue and hydrophilic ﬂuids spontaneously separate in two phases
with no need of centrifugation. The piston of the syringe is used to
take in or to expel the solutions used to wash the sample, to disso-
ciate the suctioned fat, or to extract the cells from the dissociated
adipose tissue. The syringe is hold in a vertical position using a
laboratory apparatus stand with support rings. Therefore, all the
necessary manipulations for the extraction of ASCs are performed
inside the syringe and last about 70 min. The ﬁrst step is to wash
the sample with 40 ml Dulbecco’s PBS (DPBD, with Ca2+ and
Mg2+, PAA Laboratories, Pasching, Austria) by gentle agitation.The syringe is hold vertically in the support stand for a few min-
utes to allow the separation of the phases, then the lower aqueous
phase is discarded by pushing the piston. The sample is washed
twice. To free the cells in the aqueous phase the washed adipose
tissue must be digested with the appropriate amount of Liberase
MTF-S (Roche Applied Science, Basel, Switzerland) at a ﬁnal con-
centration of 0.28 Wünsch U/ml diluted in 10 ml DPBS (with Ca2+
and Mg2+). The sample is incubated for 45 min at 37 C under con-
stant but gentle agitation. Enzymatic reaction is stopped by aspira-
tion of 30 ml of injectable 5% human albumin solution (CSL Behring
AG, Bern, Switzerland) in the syringe. The syringe is then put back
in vertical position to allow the separation of the phases. The lower
layer, which contains now the SVF cells, is carefully poured out into
a conical 50 ml centrifuge tube (TPP, Trasadingen, Switzerland).
The extracted adipose tissue is washed again with 40 ml 5% human
albumin solution to increase cell yield. Finally, after ﬁltration
through 100 and a 40 lm sieve (Cell Strainer, BD Falcon, Basel,
Switzerland), SVF is centrifuged 400g, 5 min RT and the pellet
suspended another time in DPBS (without Ca2+ and Mg2+, PAA
Laboratories, Pasching, Austria) or in tissue culture medium.
The SVF is then analyzed for cell count and number of nucleated
cells using an electronic cell counter (Hemocytometer – AxonLab
ABX Micros60).
SVF characterization by FACS analysis
The cells of the SVF were characterized by cytoﬂuorimetric
analysis using a 10 channel Navios cytometer (Beckman Coulter,
‘‘BC’’, Nyon, Switzerland), as earlier [21]. Brieﬂy, roughly
500,000 cells from fresh SVF preparation were taken and centri-
fuged 5 min at 400g. The pellet was re-suspended in 220 ll of
PBS without Ca2+/Mg2+ (Eurobio, CS1PBS01) with 1% human con-
verted AB serum (PAA, C11-021). 100 ll of cell suspensions were
put into 2 test tubes and stained with control antibodies IgG2a-
PE (BC, A12695), IgG1-KRO (BC, A96415), IgG1-APC-A750 (BC,
A71120) and Syto 40 (Invitrogen, S11351) for the control tube
and CD146-PE (BC, A07483, CD146 is a cell adhesion antigen pres-
ent mainly in endothelial cells), CD45-KRO (BC, A96416, CD45 is a
common leukocyte antigen found on all leukocytes), CD34-APC-
A750 (BC, A89309, CD34 is an hematopoietic progenitor cell anti-
gen found on hematopoietic stem cells), 7-AAD and Syto 40 for
the positive tube, respectively. All antibodies were used accord-
ingly to the manufacturer’s instructions. After 20 min of incuba-
tion, erythrocytes were lysed with 1 mL of VersaLyse (BC,
A09777). Before acquisition, 100 ll Flow-Count Fluorospheres
(BC, 7547053) were added to the test tube. Post-acquisition, the
data were analyzed with the Kaluza software (BC). Brieﬂy, the
DNA marker Syto 40 was used to exclude cellular debris (i.e. neg-
ative) and 7-amino-actinomycin D (7-AAD) was used for dead
and live cell discrimination and therefore for assessing the cellular
viability [10,18]. ASCs were identiﬁed in the CD45 and CD146 neg-
ative and CD34 positive fraction [6,21]. Finally, Flow-Count Fluor-
ospheres were used to directly determinate the absolute number of
ASCs by applying the formula: Absolute Count (cells/ll) = (Total
Number of Cells Counted/Total Number of Fluorospheres Coun-
ted)  Flow-Count Fluorospheres Assayed Concentration.
Colony-Forming Unit (CFU-F) assay
The CFU-F assay was performed as already described elsewhere
and used to evaluate the frequency of mesenchymal progenitors in
the SVF fraction. Therefore, freshly extracted nucleated cells were
plated at two cell concentrations (5000 and 10,000 cells) in stan-
dard 100  20 mm tissue culture dishes (growth area 58.95 cm2,
BD Falcon, Basel, Switzerland) and cultured in MEM/5% converted
human serum/1% antibiotics for 14 days. The plates were then
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Buchs, Switzerland)/0.2% Glutaraldehyde (AppliChem, Darmstadt,
Germany) for 5 min and stained with crystal violet solution
(Sigma–Aldrich, Buchs, Switzerland) for 10 min. After washing
the plates with water, the number of colonies were counted. A col-
ony consisting of more than 50 cells was deﬁned as a CFU-F.Table 1
Characterization of SVF in N = 44 adipose tissue samples.
Sample Volume Cells/g Viability (%) ASCs (%)Cryopreservation and thawing of SVF
Fresh SVF cells were centrifuged 5 min at 400g, re-suspended in
25 ml ice-cold solution of injectable 5% human albumin solution
with 5% ME2SO (Dimethylsulfoxide, WAK-Chemie Medical GmbH,
Steinbach, Germany) and transferred into a freezing 25 ml cryobag
(Pall Europe Ltd., Portsmouth, England). Cells were frozen by
means of a programmable freezer (Consartic GmbH, Schoellkrip-
pen, Germany) under the following ‘‘controlled-rate’’ conditions:
from 4 C to 0 C in 6 min, then hold for 15 min at 0 C. From 0 C
to 2 C in 9 min and then hold for 2 min at 2 C. From 2 C
to35 C in 25.5 min and ﬁnally from35 C to100 C in 13 min.
For what regards thawing, the cryobag was immersed in a 37 C
water bath for 2–3 min. Immediately after being thawed, the cells
were carefully aspirated, mixed with an equal volume of injectable
5% human albumin solution in a 50 ml TPP conical tube and centri-
fuged at 400g for 5 min.1 50 22,600 60.88 7.94
2 50 93,950 64.46 15.84
3 100 85,830 74.04 17.49
4 100 79,500 76.75 16.83
5 50 104,000 72.64 30.10
6 40 176,600 79.71 32.37
7 50 100,300 68.18 20.67
8 40 127,800 60.19 20.25
9 50 61,400 68.65 8.03
10 50 288,708 94.77 8.68
11 50 170,905 88.14 18.09
12 50 39,235 75.41 6.71
13 50 35,882 65.73 12.99
14 150 15,265 85.52 16.77
15 150 118,110 68.93 40.00
16 150 163,333 86.05 35.28
17 150 310,396 93.00 43.18
18 150 6,033 93.00 23.48
19 48 49,875 94.60 31.00
20 30 66,500 94.60 31.00
21 48 302,083 82.93 17.43
22 52 182,692 84.09 18.92
23 122 259,016 80.00 28.12
24 40 87,500 82.31 29.47
25 40 50,000 91.58 25.44
26 80 452,500 83.00 42.91
27 40 140,000 94.73 43.04
28 30 45,800 97.23 43.79
29 80 138,750 98.28 13.17
30 40 146,625 98.15 22.02
31 104 49,279 89.65 32.48
32 30 250,000 95.95 45.64
33 82 595,122 94.00 44.31
34 89 547,890 88.67 35.70
35 60 193,500 98.62 30.85
36 158 6,582 84.50 17.09
37 80 91,875 98.20 24.79
38 50 105,000 94.00 33.60
39 50 175,000 87.08 25.57
40 136 218,750 93.49 39.82
41 180 464,667 89.89 10.23
42 68 491,912 97.64 36.50
43 50 420,000 86.75 22.95
44 50 428,400 86.21 42.98
Fresh adipose tissue samples were processed for ASCs extraction as described.
Volume, cells/g, viability and percentage of ASCs are reported in Table. (SVF, stromal
vascular fraction; ASCs, adipose-derived stem cells.)Cell culture and differentiation
Adipose-derived mesenchymal stem cells were cultured until
passage 2 in basal Ham’s F12/IMDM (1:1) medium (Cell Culture
Technologies, Gravesano, CH) supplemented with various growth
factors and referred as to serum free medium (Patent pending).
Cells were then plated at a density of 3  103/cm2 onto multi wells
plates (PureCoat ECM Mimetic Cultureware, BD Biosciences,
Bedford, USA) for induction. Half of the wells cells were cultured
in the conditions speciﬁed here above, i.e. serum free medium (basal
Ham’s F12/IMDM (1:1) medium supplemented with growth factors)
and referred as non-induced cells, whereas in the remaining wells
cells were induced to osteoblasts, adipocytes and chondrocytes by
means of different induction media. For osteoinduction we used
the serum free medium supplemented with 3 mM Sr2+ and 10–
200 nM Vitamin D. Cell differentiation was conﬁrmed at day 21
by Alizarin Red staining. Brieﬂy, the cells were ﬁxed in 10% forma-
lin for 30 min RT and incubated 30 min RT in Alizarin Red staining.
The formation of red calcium deposits is a marker of osteogenic dif-
ferentiation. For adipogenic induction serum free medium was
supplemented with Epidermal Growth Factor (EGF, cyt-217, ProS-
pec-Tany Technogene Ltd., East Brunswick, USA) and Rosiglitazone
(Sigma–Aldrich, Buchs, Switzerland). Adipogenesis was assessed
by Oil Red staining. Brieﬂy, cells ﬁxed in 10% formalin for 30 min
RT were incubated in fresh Oil O Red water solution for 5 min
RT. Induced cells were visible as cells containing consistent red
deposits in vacuoles. Chondrogenic differentiation was assessed
by induction of ASCs using the micro mass method. Brieﬂy, ASCs
were gently centrifuged in a 15 ml conical tube to form small pel-
lets and then cultured for 21 days in the serum free medium sup-
plemented with sodium pyruvate, Bone Morphogenic Protein 6
(BMP6), Transforming Growth Factor Beta 3 (TGF-beta3), Fibro-
blast Growth Factor beta (beta-FGF) and Prostaglandin E2 (PGE2).
Chondrogenic pellets were ﬁxed in 10% formalin for 30 min RT.
Samples were then embedded in parafﬁn and sections stained with
Alcian Blue. Control cells did not retain a spheroid shape and
showed no speciﬁc staining while induced cells showed a strong
blue signal.Results
We analyzed the adipose-derived stromal vascular fraction of
more than 130 liposuction procedures. We show here the obtained
data from N = 44 adipose tissue samples before cell culture. On
average, we obtained 75.3 g of fat tissue per sample and 180,890
total nucleated cells/g. The procedure developed in our laboratory
allows the extraction of nucleated cells in a safe and the reproduc-
ible way by showing an average cell viability of 85.05% as mea-
sured by 7-AAD stain (Table 1 and Fig. 1, left panel).
ASCs cells were characterized by FACS analysis and considered
to be CD45 and CD146 negative and CD34 positive. On the 44 sam-
ples considered we found an average of 26.44% of ASCs, following
the characterization by FACS method (Fig. 2).
ASCs were then checked for the ability to form CFU-F colonies.
The average value for colony formation in fresh samples was
5.8  103 colonies, where a colony was deﬁned to have more than
50 clonal cells (Table 1). We also checked the CFU-F after thawing
by seeding cells at three different concentrations for three different
Fig. 1. Viability of stromal vascular fraction cells before and after a freeze/thaw cycle. FACS analysis for 7-AAD stain in fresh extracted SVF cells (left) and the same sample of
SVF cells thawed after a freeze cycle (right). Dead cells are gated at the right of both panels. (7-AAD, 7-amino-actinomycin; SS, side scatter.)
Fig. 2. FACS analysis of fresh adipose-derived SVF cells. FACS analysis for the
characterization of ASCs in fresh extracted SVF. ASCs cells are CD45, CD34+ and
CD146 and are gated in the right lower panel. (FACS, ﬂuorescent activated cell
sorter; ASCs, adipose-derived stem cells; SVF, stromal vascular fraction; CD, cluster
of differentiation.)
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affect the clonogenic ability of ASCs. Conversely, the CFU-F number
was shown to increase after thawing (data not shown).
The fresh SVF cells were successively challenged by a freezing
and thawing cycle. N = 15 samples were used in the freezing/thaw-
ing procedure as described above. SVF samples ranging from
6.66  105 to 3.94  106 total cells were taken in consideration.
Table 2 shows the results of these experiments. Cell samples were
kept frozen for periods ranging from 14 to 193 days. Viability of
SVF cells was measured by FACS analysis and gave an average
value of 89.6% ranging from 81% to 98%. The total ASCs content
of each fresh sample ranged from 237,938 to 1,092,925 with an
average value of 587,753 cells. After thawing, cells were counted
for ASCs number and viability. We could demonstrate the viability
results over 15 samples, ranging from 71.7% to 98.3% and average
recovery rates of 79.82% of living ASCs after the freeze/thaw
procedure.
Alive cells after a freezing/thawing cycle are important because
the freezing process prolongs cells’ life and makes them available
for future therapies based on expanded ASCs. To check whether
the thawed cells can grow and differentiate again after the freez-
ing/thawing cycle, we cultivated and differentiated 3 samples of
thawed SVF-cells in 0.1% human serum supplemented medium.The results are showed in Fig. 3. Three different samples were pla-
ted at 3000 cells/cm2 and cultured for 20 days. Cells showed a clas-
sical growth pattern with an early lag-phase in the ﬁrst 7 days and
a subsequent exponential growth. After 20 days in culture, cells
reached a concentration of 42,550 cells/cm2 i.e. a 13 expansion
of the initial seeded number.
The same cells were induced to differentiate into adipocytes,
osteocytes and chondrocytes and representative results are shown
in Fig. 4. Cells were clearly inducible to the speciﬁed phenotypes.
Oil Red staining evidenced adipoinduction by red deposits in vac-
uoles (Fig. 4, panel A: induced and D: control), whereas Alizarin-
S staining was used for osteoinduction and showed the formation
of red calcium deposits as a marker of osteogenic differentiation
(Fig. 4, panel B: induced and E: control). Sections of chondro-
induced samples stained with Alcian Blue showed a strong blue
signal (Fig. 4, panel C, induced and F, control). We found all tested
samples to be inducible for the differentiation of adipocytes, osteo-
cytes and chondrocytes.Discussion
Tissue engineering keeps promise for the restoration of the soft
tissue esthetic function and for the treatment of known diseases
that have currently no therapy option [22]. In this regard, the stor-
age of ASCs is still for long time the initial step for future cell ther-
apies using ASCs for regenerative purposes. There are actually
more than 60 clinical trials worldwide involving ASCs in the treat-
ment of human disease (clinicaltrials.gov [9]). Current standard
clinical strategies for soft tissue augmentation primarily include
the use of synthetic implants and ﬁllers. However, various compli-
cations derived from the foreign body, such as capsular contracture
or displacement, lead to implant removal or replacement at a
relatively high rate.
Free fat transfer gives unpredictable results, where graft reab-
sorption can vary between patients, although it seems to work well
for small defects correction [4].
Mixing autologous ASCs with a portion of suctioned fat and
injecting subcutaneously back into the target site is another
strategy which is recently used to overcome these problems and
to provide a ‘‘living scaffold’’ for stem cells [27].
It has become crucial to develop safe and reproducible protocols
for the extraction and storage of ASCs that can adhere to the strict
European regulation concerning the Advanced Therapy Medicinal
Products (ATMPs). Storage of the SVF could be seen as an interme-
diary GMP product to be needed in the future for many differenti-
ation protocols to be developed. One step in this direction is the
possibility to store frozen cells for long periods of time in liquid
Table 2
Post-thaw characterization of SVF in N = 15 adipose tissue samples.
Sample no. Pre-thaw Post-thaw
Total SVF cells Total ASCs Viability (%) Total ASCs recovered ASCs recovery (%) Viability (%)
1 1,681,603 726,185 93.00 691,000 95.15 88.25
2 840,801 363,093 93.00 265,000 72.98 91.65
3 852,300 237,938 98.00 179,000 75.23 76.56
4 1,704,600 475,876 98.00 363,000 76.28 91.80
5 1,704,600 475,876 98.00 344,000 72.29 77.05
6 666,667 288,084 93.00 197,000 68.38 88.75
7 666,667 288,084 93.00 190,000 65.95 89.86
8 3,949,910 1,092,925 89.00 1,228,000 112.36 98.29
9 1,265,923 334,800 81.25 252,000 75.27 93.06
10 835,625 276,250 89.67 229,000 82.90 82.90
11 3,949,910 1,092,925 89.00 919,000 84.09 75.72
12 3,949,910 1,092,925 89.00 874,000 79.97 71.72
13 3,180,288 868,269 79.60 539,000 62.08 88.16
14 3,180,288 868,269 79.60 539,000 62.08 88.16
15 1,265,923 334,800 81.25 376,000 112.31 84.08
SVF samples were characterized for total cell content, total ASC content and viability and frozen in 10% DMSO in liquid nitrogen following the protocol described in Materials
and Methods. Post-thawing results are shown for ASCs recovery and percentage of viability recovered after the freeze cycle.
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Fig. 3. Growth curve of frozen/thawed ASCs. N = 3 samples (gray lines) of adipose-
derived mesenchymal stem cells (ASCs) submitted to a freeze/thaw cycle were
cultured for 21 days in a medium supplemented with 1% human serum. (ASCs,
adipose-derived stem cells; red line = mean ± SEM). (For interpretation of the
references to color in this ﬁgure legend, the reader is referred to the web version of
this article.)
Fig. 4. Differentiation assay of thawed ASCs. Cells were grown conﬂuent to 70% and ind
performed as described in Materials and methods, where, induced and non-induced samp
for osteocytes and Alcian Blue staining for chondrocytes were used. Induced cells incub
vacuoles (Panel A: induced cells; panel D: control); osteocytes induction, evaluated wit
inducted cells, Panel E: control) and chondrocyte induction, as evaluated by Alcian Blue s
arrows) and several chondrocyte-like cells (dashed circles at arrowhead points) as compa
ﬁbers can be evidenced (black arrows), chondrocyte-like cells cannot be clearly identiﬁ
derived stem cells.)
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ampliﬁcation and/or differentiation.
We show here that SVF extracted cells can be frozen and
thawed without losing their ability to grow and differentiate in
mesenchymal-speciﬁc lineages.
Only a few studies examined the role of frozen storage of adi-
pose tissue. One of them has recently described the storage of
entire adipose tissue at various temperatures for periods longer
than 1 year to see whether the tissue was still capable of adipo-
genic differentiation. Cells isolated from the tissue proved to be a
reliable source of human ASCs and adipocytes [11]. Early research
studies described a domestic 18 C storage of adipose tissue for
2 weeks. Injection of fat tissue in nude mice demonstrated the sur-
vival of this tissue as compared to a control group of non-frozen
tissue [19]. A simple freezing technique was recently used by stor-
ing fat tissues at 196 C in liquid nitrogen for up to 8 days dem-
onstrating a good maintenance of mitochondrial metabolic
activity in the frozen grafts [12]. Remarkably, in both experiments
fat tissue samples were frozen without the addition of a cryopro-uced for 9 days to differentiate to osteo-, chondro- or adipo-lineages. Staining was
les were treated the same way. Oil-O-Red staining for adipocytes, Alizarin-S staining
ated in fresh Oil-O-Red were visible as cells containing consistent red deposits in
h Alizarin-S staining, is shown by the formation of red calcium deposits (Panel B:
taining, show in Panel C (induced cells) robust ﬁber tracts of collagen matrix (black
red to Panel F (control non-induced) where only marginally developed collagen-like
ed and Alcian Blue stained areas are rather sparse (arrowheads). (ASCs, adipose-
216 G. Minonzio et al. / Cryobiology 69 (2014) 211–216tective agent. Another study reported the use of a cryoprotective
agent to better save and keep viable tissues after thawing [26].
Nevertheless, we have to consider that adipose tissue is the
source of ASCs responsible for the biological effect observed in
regenerative medicine. Thus, for long conservation purposes we
should only consider the stromal vascular fraction (SVF) by isolat-
ing it from the carrier tissue. Indeed, the vast majority of studies
report the separation, growth and differentiation of the SVF and
all clinical trials to date using ASCs have been designed on this par-
ticular fraction of cells, where a large number of stem cells have
been found.
Published studies about the cryoconservation of human SVF-
cells extracted from adipose tissues are rare (for a review see
[24]). Recently, it has been described a method for liquid nitrogen
storage of SVF-cells [5], where thawed SVF-cells has been shown
to differentiate into adipocytes and endothelial cells. Unfortunately,
this study used a freezing medium containing fetal bovine serum
thus avoiding the possibility to use cells as an Advanced Cell Ther-
apy Product.
The presence of serum in the freezing medium was also chal-
lenged in another study and reported to be not necessary by the
authors. They suggested indeed that post-thaw ASCs viability, adi-
pogenic and osteogenic differentiation can be maintained even
when ASCs cells are frozen in the absence of serum but with a min-
imal concentration of 2% ME2SO in DMEM [23], which represents a
step forward to the use of these cells as therapeutic agents. Other
reagents like sericin, a protein hydrolysate very rich in serine, has
been used in the freezing medium and found to be effective on the
survival of ASCs and in their differentiation potential [13].
MSCs are pluri-potential cells and can thus give rise to many
target tissues, like bone, tendons, cartilages, heart and nerves,
opening the door to the real world of Advanced Therapy Products
that, in a ﬁrst time, will be autologous-based but could in the near
future be engineered to everyone’s need.
We designed and validated a protocol to extract and freeze SVF
stem cells from adipose tissues that allows thawed cells to main-
tain their growth and differentiation potential. Overall, our data
show that the SVF can be easily frozen following deﬁned standard
conditions for cell freezing. The yield after the procedure, in terms
of cell survival number and percentage of viable cells, is high
enough to be safely used for banking purposes.
These results need further conﬁrmation and we are actively
working on the GMP-validation of the whole process to be able
to store SVF-cells as a real medicinal drug, allowing thus the
patient to dispose of his own cells for cell therapies in the near
future.
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